Core Viewpoint - The approval of SYH9089 injection by the National Medical Products Administration of China marks a significant advancement for the company in the field of postoperative analgesia, addressing a critical clinical need for long-lasting pain relief solutions [1] Group 1: Product Development - The product, SYH9089, is designed to inhibit sodium ion channels in nerve cells, providing reversible blockage of impulse conduction along nerve fibers [1] - It aims to reduce the frequency of administration, fulfilling the continuous pain relief requirements post-surgery and decreasing reliance on opioid medications [1] - The product can extend the duration of analgesia from a single dose to one week, potentially becoming the first ultra-long-acting analgesic in China [1] Group 2: Clinical Research and Safety - Preclinical studies indicate that SYH9089 does not exhibit systemic toxicity or new toxic organ targets, showing significant long-lasting analgesic advantages compared to existing ropivacaine injections [1] - The approved clinical indication for the product is postoperative pain relief, highlighting its potential to meet urgent clinical demands in the ultra-long-acting postoperative analgesia sector [1]
石药集团(01093.HK)：罗哌卡因长效注射液(SYH9089注射液)在中国获临床试验批准